Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Dina Kokh"'
Publikováno v:
International Journal of Gynecological Pathology. 41:235-243
In the female genital tract, rhabdomyosarcoma may occur in "pure" form or as a heterologous constituent of a biphasic neoplasm such as carcinosarcoma or adenosarcoma. Discriminating rhabdomyosarcoma from its histologic mimics relies on confirmation o
Autor:
Cheryl Ewing, Gretchen M. Ahrendt, Anne M. Wallace, Gregor Krings, Helen Krontiras, Christina Yau, Kimberly Cole, Sunati Sahoo, Julie E. Lang, Dina Kokh, Brigid K. Killelea, Akiko Chiba, Tod Tuttle, W. Fraser Symmans, Molly Klein, Arpana Naik, Yunn-Yi Chen, Marie Osdoit, Constantine Godellas, Roshni Rao, Nora Jaskowiak, Laura J. Esserman, Bev Parker, Julia Tchou, Rita A. Mukhtar, Ronald Balassanian, Smita Asare, Jodi M. Carter, M. Catherine Lee, Eleni A. Tousimis, Laila Khazai, Shannon Tierney, Judy C. Boughey, Rachael Lancaster
Publikováno v:
Cancer Research. 80:P3-08
Background: Patients who achieve a pathological complete response (pCR- defined as no invasive cancer) after neoadjuvant chemotherapy (NAC) for breast cancer (BC) have improved outcomes, but there is still controversy about the significance of residu
Autor:
Michelle E. Melisko, Kirsten K. Edmiston, HS Han, W. Fraser Symmans, Gregor Krings, Molly Klein, Rita Nanda, Claudine Isaacs, Rebecca K. Viscusi, Sunati Sahoo, David M. Euhus, Jeffrey B. Matthews, Angela DeMichele, Erica Stringer-Reasor, Qamar J. Khan, Laura J. van't Veer, Tara Sanft, Christina Yau, Donald A. Berry, Richard Schwab, Janice Lu, Jane Perlmutter, A. Jo Chien, Donald W. Northfelt, Anne M. Wallace, Zaha Mitri, Jane L. Meisel, Julie E. Lang, Jodi M. Carter, Lajos Pusztai, Hope S. Rugo, Rachel L. Yung, Erin D. Ellis, Anthony D. Elias, Laila Khazai, Kathy S. Albain, Yunn-Yi Chen, Nola M. Hylton, Amy S. Clark, Laura J. Esserman, Christos Hatzis, Judy C. Boughey, Douglas Yee, Kimberly Cole, Dina Kokh
Publikováno v:
Cancer Research. 80:P2-20
Background: Achieving a pathologic complete response (pCR) has been shown on the patient level to predict excellent long-term event-free survival outcomes. Residual cancer burden (RCB) quantifies the extent of residual disease for patients who did no
Autor:
Jane Wei, Jodi M. Carter, Laila Khazai, Laura J. van't Veer, Molly Klein, Gregor Krings, Dina Kokh, Kimberly Cole, Yunn-Yi Chen, Lamorna Brown-Swigart, Ronald Balassanian, Sara J. Venters, Laura J. Esserman, Bev Parker, Amy L. Delson, Christina Yau, Sunati Sahoo, W. Fraser Symmans, Denise M. Wolf
Publikováno v:
Cancer Research. 80:P6-10
Background: The I-SPY 2 TRIAL enrolls women with locally advanced, molecular high-risk breast cancer. An integrated Residual Cancer Burden (iRCB), based on MRI volume change through treatment, is used to predict pathologic complete response (pCR) in
Publikováno v:
AJSP: Review and Reports. 21:28-31
Publikováno v:
International Journal of Gynecological Pathology. 34:351-356
Low-grade appendiceal mucinous neoplasms (LAMNs) are commonly associated with deposition of mucin, with or without admixed low-grade epithelium, on peritoneal surfaces (pseudomyxoma peritonei). We describe a very rare presentation of LAMN as extensiv
Publikováno v:
Pathology Case Reviews. 18:105-110
Publikováno v:
AIDS Research and Human Retroviruses. 32:4-5
Publikováno v:
Journal of the American Society of Cytopathology. 3:S27
Publikováno v:
The Journal of Immunology. 188:113.9-113.9
Rationale: The role of IgE in immunity against Hepatitis A has not been studied. Methods. Serum was obtained from an adult who was vaccinated with Hepatitis A virus (HAV) (Havrix®) in 2005 and again in 2009 and compared with pre vaccination status a